Summary

This AI-generated content is provided without warranty, with no liability accepted for reliance on it. Learn more.

• Zontivity (vorapaxar) is indicated for the reduction of thrombotic cardiovascular events in patients with a history of myocardial infarction (MI) or peripheral arterial disease (PAD).
• This summary is based on the review of two systematic review(s)/meta-analysis(es). ^[1-2]
• Vorapaxar significantly reduced limb ischemia and revascularization in patients with peripheral artery disease (PAD) compared to placebo, indicating its beneficial effect on these specific outcomes.
• Vorapaxar, along with picotamide, dipyridamole with aspirin, and ticlopidine, significantly lowered the risk of all-cause mortality compared to aspirin in the patient population studied.
• Clopidogrel significantly reduced the risk of major adverse cardiovascular events (HR 0.78; 95% CrI 0.65-0.93) compared to aspirin, without an associated increase in bleeding risk.
• There is no specific bleeding risk data available for vorapaxar within the reviewed studies, though the safety profile is implied to be comparable to other antiplatelet therapies.
• Dual antiplatelet therapy with clopidogrel plus aspirin and rivaroxaban plus aspirin significantly increased major bleeding risk compared to aspirin alone.
• Vorapaxar is particularly effective in reducing limb ischemia and revascularization in patients with peripheral artery disease (PAD), and clopidogrel is noted for its benefit in reducing major adverse cardiovascular events in this population. Additionally, in patients with chronic coronary artery disease (CAD), the combination of rivaroxaban plus ASA significantly improves cardiovascular outcomes, though it increases the risk of major bleeding.